The government announced on February 8, 2019 by a joint statement of Frédérique Vidal, Minister of Higher Education, Research and Innovation, and Guillaume Boudy, Secretary General for Investment his decision to extend for 5 years the VRI - Labex Vaccine Research Institute following the positive evaluation carried out by the international jury.
Created in 2011 in the first wave of the “programme d’investissement d’avenir” (PIA1), the VRI has implemented a new and innovative vaccinology approach via “reprogramming” the immune system through the development of vaccines based on the most recent knowledge of basic immunology, innovative route of vaccination and/or combined prime boost strategy, and an integrated approach for the high-fidelity evaluation of vaccine/immunomodulatory strategies.
As highlighted by the ANR international jury, the VRI has reached key objectives: i) the development of innovative vaccines from discovery concepts to in vitro validation and basic knowledge; ii) the development of new strategies from preclinical models to phase I/II clinical trials; iii) the set-up of innovative technological platforms to evaluate these vaccines strategies; iv) a Master 2 degree program for dissemination of vaccine knowledge at national and European level and the participation to a graduate school in Digital Public Health (Bordeaux University).
This integrated program led us to select for manufacturing the first generation of DC-based vaccines that will enter phase I/II clinical trials in 2019, according to the primary objective of the VRI stated in 2011.
In the future, the labex will concentrate its efforts on the clinical evaluation of these candidate vaccines with the ultimate goal to select the best-in-class strategy that will be pushed in further clinical development plans. This will require the continuation of an ambitious program associating the improvement of the concepts of vaccine tools and strategies, their down-selection in the preclinical models and a better understanding of the mechanisms of vaccine responses. The expertise and know-how developed in the consortium put us in an excellent position and guarantee the success of the program.
The European HIV Vaccine Alliance (EHVA) announces the start of the EHVA T01 / ANRS VRI05 trial, with the initiation of screening of participants at the Lausanne University Hospital Switzerland. EHVA-T01 / ANRS VRI05, a phase I/II placebo-controlled randomised trial, will evaluate a combination of experimental therapeutic HIV vaccines and an experimental immunotherapy drug in people living with HIV across six countries in Europe - France, Germany, Italy Spain, Switzerland, and UK. Prof Yves Lévy is the coordinating investigator of EHVA-T01/ ANRS VRI05, which is sponsored by Inserm-ANRS and managed by The Medical Research Council Clinical Trials Unit at University College London.
Prof Yves Lévy, director of the VRI, is the coordinator of the EHVA consortium, a five year project funded by the European Union’s Horizon 2020 Research and Innovation Programme designed to foster the development of an effective vaccine (www.ehv-a.eu). The EHVA encompasses 39 partners, each with the expertise to promote a comprehensive approach to the development of an effective HIV vaccine.
In parallel to the 30th edition of the World AIDS Day that will take place on December 1st, the VRI and its partners, UPEC and Inserm, are organizing a day dedicated to the fight against AIDS in Créteil.
In the program:
Program of the conference
I. Current situation of HIV vaccine clinical research - Jean-Daniel Lelièvre (Vaccine Research Institute)
II. Recruitment and Engagement of "Volunteers" in Clinical Trials - Caroline Ollivier-Yaniv (Ceditec, Vaccine Research Institute)
III. Vaccination and mistrust - Annick Opinel (Institut Pasteur)
IV. Roundtable with Speakers and Representatives of UPEC Student Associations
Led by Nicolas Manel, VRI and Inserm researcher, the NONO study brings a better understanding of the natural mechanisms of the control of HIV infection and opens the way to new steps in vaccine research against this virus.
This study is supported by ANRS. The work was published in the journal Cell.
The HIV R4P conference will be held in Madrid from 21 to 25 October 2018.
The VRI will be present with a satellite symposium "Social Sciences in Vaccine Trials: A Booster to Recruit Volunteers" to be held on Sunday, October 21st from 12:30 to 2:30 pm organized jointly with the ANRS.
As an extension of the book of the Social Sciences and AIDS collection "Recruitment-commitment in clinical trials in prevention" was published the October 2018 supplement of the JAIDS (Journal of the Immune Deficiency Syndrome) entitled "Volunteers for HIV vaccine trial : A social science approach ", supported by the VRI and the ANRS.
To combat the re-emergence of vaccine-preventable diseases, a joint European Joint Action on Vaccination (EU-JAV) platform, coordinated by Inserm, was launched on 4 September 2018 with 19 other European countries. The aim is to restore confidence and put in place effective measures to restore sufficient immunization coverage in all the countries involved. This action will be funded for three years with a budget of € 5.8 million, of which € 3.5 million from the European Union Health Program. Prof. Jean-Daniel Lelièvre (VRI) is at the head of WP7 - Vaccine research and development: priority-setting framework.
The annual meeting of the VRI took place on the 14th of June 2018 at Biopark in Paris.
Yves Lévy presented the hightlights for the year and futur.
Mary Suzan, INSERM UMR1252 SESSTIM Méditerranée Infection was the keynote speaker and presented "Social sciences and HIV research: from prevention to HIV cure trials andfrom patients' experience reports to community-based research"
The ANRS and the VRI publish a collective work that addresses when HIV-negative individuals agree to participate in a HIV preventive clinical trial. The book is released in the collection "Social Sciences and AIDS" and is available freely on the ANRS website. Yves Lévy and François Dabis signed his preface.